COX-2 inhibitors and the cardiovascular system: is there a class effect?

September 2005    Volume 12, Issue 5   Br J Cardiol 2005;12:387-91

Authors:
Mohamed Bakr, Derek G Waller

Selective inhibition of COX-2 preferentially inhibits the production of prostaglandins responsible for vasodilation and inhibition of platelet aggregation. This potentially creates a pro-thrombotic state. This review examines the evidence that selective COX-2 inhibitors have adverse effects on the heart and circulation. The risk of myocardial infarction and other vascular ischaemic events, the effects on blood pressure and decompensation of treated heart failure are discussed. Conclusions are drawn about the relative risk with the different members of the drug class, and recommendations for clinical practice presented.

back to top

Comments

There are currently no comments for this article - leave a comment

You must be logged in to post a comment.
Not yet a member? Register now for free.

back to top